Neurol India Home 
 

BRIEF REPORT
Year : 2021  |  Volume : 69  |  Issue : 5  |  Page : 1363--1367

Clinical and Molecular Features of First Mexican Friedreich's Ataxia Patients with Compound Heterozygous FXN Mutations

Marie Catherine Boll1, Dianela Gasca-Saldaña1, Yerye Gibrán Mayén-Lobo2, David José Dávila-Ortiz de Montellano3, Nancy Monroy-Jaramillo3 
1 Clinical Research Laboratory, Ataxias, Chorea and Other Rare Neurodegenerative Diseases, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez” (INNNMVS), Mexico City, Mexico
2 Department of Genetics, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”; Department of Biological Systems, Metropolitan Autonomous University-Xochimilco, Mexico City, Mexico
3 Department of Genetics, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico

Correspondence Address:
Nancy Monroy-Jaramillo
Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Ave. Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Mexico City
Mexico

Background: Friedreich's ataxia (FRDA) is caused by homozygous GAA repeat expansions or compound heterozygous (CH) mutations in FXN gene. Its broad clinical spectrum makes it difficult to identify, thus an accurate diagnosis can only be made by genetic testing. Objective: This study aims to present data on FXN variants observed in patients with sporadic or recessive ataxia, including detailed data of the first CH Mexican patients. Materials and Methods: One hundred and eight patients with recessive or sporadic cerebellar ataxia were referred to our institution between 2009 and 2019 for FXN molecular testing. This was achieved using a combined methodology of triplet repeat-primed PCR (polymerase chain reaction), long PCR, FXN sequencing and multiplex-ligation probe-amplification. Results: Eighteen patients had a homozygous FXN genotype; whereas five were CH patients with a slow progression and phenotypic variability, including a late-onset case with spastic paraparesis, and a Charcot-Marie-Tooth-like case. Conclusions: These first Mexican CH patients pose important implications for genetic counseling and FRDA management.


How to cite this article:
Boll MC, Gasca-Saldaña D, Mayén-Lobo YG, Dávila-Ortiz de Montellano DJ, Monroy-Jaramillo N. Clinical and Molecular Features of First Mexican Friedreich's Ataxia Patients with Compound Heterozygous FXN Mutations.Neurol India 2021;69:1363-1367


How to cite this URL:
Boll MC, Gasca-Saldaña D, Mayén-Lobo YG, Dávila-Ortiz de Montellano DJ, Monroy-Jaramillo N. Clinical and Molecular Features of First Mexican Friedreich's Ataxia Patients with Compound Heterozygous FXN Mutations. Neurol India [serial online] 2021 [cited 2022 Jan 21 ];69:1363-1367
Available from: https://www.neurologyindia.com/article.asp?issn=0028-3886;year=2021;volume=69;issue=5;spage=1363;epage=1367;aulast=Boll;type=0